Guggenheim Reaffirms “Buy” Rating for Mineralys Therapeutics (NASDAQ:MLYS)
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports. Several other brokerages have also recently issued reports on MLYS. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in […]
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a note issued to investors on Monday,Benzinga reports. Several other brokerages have also recently issued reports on MLYS. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in […]
